ClinicalTrials.gg
RecruitingNCT05662189Updated Mar 18, 2025

Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

An interventional study of 68Ga-exendin-4 and mixed meal test in Type1diabetes, Type2diabetes and Pre Diabetes, sponsored by Azienda Ospedaliero-Universitaria di Parma. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Azienda Ospedaliero-Universitaria di Parma · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Mar 2022, registered Dec 2022).
  • Started Mar 2022; still recruiting 4 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.

Read the detailed description

Pancreatic beta cell functional mass (BCFxM) can be loosely defined as the product of beta cell mass (BCM) multiplied by beta cell function (BCF). Current in vivo methods (e.g. hyperglycemic clamp, intravenous glucose tolerance test, oral glucose tolerance test, mixed meal tolerance test) actually assess BCFxM, not beta cell function per se. Loss of BCFxM is at the heart of the etiology and pathogenesis of both type 1 (2) and type 2 diabetes mellitus. In the former, destruction of beta cell mass by autoimmune insulitis is the the primary determinant of BCFxM loss. In the latter, beta cell mass loss is about 25-35% and keeps increasing with the duration of the disease, but an additional key role is played by the loss of beta cell function. Previous dogma held that in type 1 diabetes complete destruction of beta cells was achieved within ≈5 years from diagnosis. Recent data have challenged this concept and shown that residues of both beta cells and BCFxM (i.e. nutrient-stimulated C-peptide secretion, which is equimolar and simultaneous to insulin secretion and is a much better biomarker of BCFxM than insulin concentration) are detectable even decades after diagnosis. Exendin-4 has been already labeled with a positron emitting nuclide and made amenable to PET imaging for diagnostic purposes. Under rigorous experimental conditions, beta cell standardized uptake per volume (SUV) of the ligand could be assessed. Furthermore, current PET-CT instruments can also provide a measure of pancreatic volume BCFxM can be determined accurately by mathematical modeling of relatively simple tests, such as a mixed meal.

The investigators will assess the relative roles of beta cell mass (BCM) and beta cell function (BCF) in two polar BCFxM groups : people with long-standing type 1 diabetes (close to 0 BCFxM) and obese people with normal glucose regulation (highest expected BCFxM), i.e. the investigators will test our method in a negative control (type 1 diabetes) and in a strongly positive control (uncomplicated obesity). A group of lean controls will be studied to ascertain that their BCMs, as determined by 68GA-exendin-4 PET-CT, fall, as they should, in the intermediate range between type 1 diabetes and obesity.

02

Conditions studied

  • Type1diabetes
  • Type2diabetes
  • Pre Diabetes
  • Hyperinsulinism

Keywords

  • diabetes
  • beta-cell
  • exendin
  • PET-CT
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's planned enrollment of 70 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 44 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years; ≤ 75 years
  • Both sexes
  • Good health
  • Absence of exclusion criteria
  • Able to understand methods, goals, and implications of the research and of delivering a free, written

Exclusion criteria

Exclusion Criteria:

  • \< 12 g/dl
  • > 10%
  • Pregnancy or breast-feeding
  • If not in menopause, women not using effective methods or not willing to undergo a pregnancy test
  • History of severe psychiatric disorder or alcohol abuse
  • Recent head traumas (\<6 months)
  • Active neurologic diseases
  • Claustrophobia
  • Active malignant neoplasms
  • Severe kidney and/or liver disease
  • Recent (\<6 months) major adverse cardiovascular events
  • Heart failure (class 3-4)
  • Drugs known to affect beta cell function and/or insulin sensitivity
  • Current or past treatment with GLP1R-agonists
  • Intolerance to exenatide
  • Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and/or insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency
  • on day time oxygen therapy
  • Any current acute disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Other
    long standing type 1 diabetes (> 20 yrs)

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    newly diagnosed type 1 diabetes (< 5yrs)

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    long standing type 2 diabetes (> 20 yrs)

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    newly diagnosed type 2 diabetes (<6 months)

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    pre-diabetes

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    hyperinsulinemic

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

  • Other
    control

    68Ga-exendin4 PET-CT scan +mixed meal test

    Drug: 68Ga-exendin-4 · Other: mixed meal test

Interventions

  • Drug68Ga-exendin-4

    68Ga-exendin4 PET-CT scan

  • Othermixed meal test

    before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

06

What researchers measure

Primary outcomes

  1. BCF x M

    BCFxM=parameters derived from mixed meal test Beta cell function(BCF)=BCFxM/BCM

    Time frame: through study completion, an average of 3 months after enrolment

  2. pancreatic beta cell mass (BCM)

    Beta cell mass index (BCM) = 68GA-exendin-4 Standard Uptake Value (SUV)\*pancreatic volume

    Time frame: through study completion, an average of 3 months after enrolment

  3. pancreatic beta cell function (BCF)

    BCFxM/BCM

    Time frame: through study completion, an average of 3 months after enrolment

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05662189
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Collaborators
University of Parma
Responsible party
Riccardo Bonadonna (Prof, Azienda Ospedaliero-Universitaria di Parma) — Principal investigator
First posted
Dec 22, 2022
Start date
Mar 15, 2022
Primary completion
Jul 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 18, 2025

Study contacts

Riccardo Bonadonna, MD
Contact
riccardo.bonadonna@unipr.it
+390521033307
Riccardo Bonadonna, MD
principal investigator · Azienda Ospedaliero Universitaria di Parma, University of Parma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion